نتایج جستجو برای: exjade
تعداد نتایج: 52 فیلتر نتایج به سال:
The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population. After 1 year, median serum ferritin decreased significantly from 3254 ng/mL at baseline to 1854 ng/mL (P < .001). Decreases occurred in chelation-naiv...
Treatment of iron overload using deferoxamine (DFO) is associated with significant deficits in patients' health-related quality of life (HRQOL) and low treatment satisfaction. The current article presents patient-reported HRQOL, satisfaction, adherence, and persistence data from β-thalassemia (n = 274) and myelodysplastic syndrome (MDS) patients (n = 168) patients participating in the Evaluatio...
Deferasirox (Exjade) is a once-daily, oral iron chelator approved for the treatment of transfusional iron overload. This study was conducted to analyze changes in cystatin C concentration, an endogenous marker of glomerular filtration rate (GFR), in patients with thalassemia receiving daily deferasirox therapy over a period of at least 9 months. One hundred and fifty beta-thalassemia patients w...
آهن از اهمیت بنیادی برای رشد، تکوین و زندگی همه موجودات زنده برخوردار است. سیستم¬های بیولوژیکی متعددی برای جذب، استفاده، ذخیره سازی و تعادل حیاتی آهن در میکروب ها، گیاهان و پستانداران توسعه یافته اند. جذب آهن به طور کلی محدود است و در گونه¬های عالی¬تر اغلب کمبود آهن دیده می شود، اما ممکن است اضافه بار آهن نیز رخ می دهد. از لحاظ کمی، آهن مهمترین عنصر کمیاب ضروری و مهمترین ماده معدنی است که برا...
Reports are emerging of hematologic responses associated with iron chelation therapy; however, studies are limited in aplastic anemia patients. Deferasirox reduced iron overload in aplastic anemia patients enrolled in the EPIC (Evaluation of Patients' Iron Chelation with Exjade(®)) study (n=116). A post hoc analysis of hematologic responses was conducted on 72 patients with evaluable hematologi...
Although blood transfusions are important for patients with anemia, chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload lead to significant morbidity and mortality, if untreated. Although the current reference standard iron chelator deferoxamine has been used clinically for over four decades, its effectivene...
This work reports a facile sonochemical route in the synthesis of nano particle of deferasirox for the first time. One application of nanotechnology is in improvement of available treatments for various diseases. Deferasirox (ICL670 or Exjade) is a tridentate chelating agent for removing transfusion overload iron in thalassemia patients. In the present work, deferasirox was prepared in nano size...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید